首页> 外文期刊>Ukrainian Biochemical Journal >The concentration of ceruloplasmin in blood of tumor-bearing rats after administration of a dirhenium(III) compound and cisplatin
【24h】

The concentration of ceruloplasmin in blood of tumor-bearing rats after administration of a dirhenium(III) compound and cisplatin

机译:施用甲状腺(III)化合物和顺铂后肿瘤大鼠血液血液浓度

获取原文
       

摘要

Contemporary investigations of mechanisms of resistance to platinides showed the key role of copper metabolism in cancer patients and proposed possible methods to attenuate the resistance by modulation of copper transporting mechanisms. In this vein, investigation of ceruloplasmin (Cp) levels – the main copper-containing protein in blood, in experiments with tumor-containing animals upon cytostatics administration is topical and has great importance. The concentration of Cp was measured in the serum of tumor-bearing rats with ordinary (T8) and resistant to cisplatin (T8*) Guerin’s carcinoma upon administration of cisplatin and quadruple bonding dirhenium(III) compound dichlorotetra-μ-isobutyratodirhenium(???) (I) in different medicamental forms. It was shown that development of tumor in T8 group led to increasing of concentration of Cp in 3.7 times and in T8* group – more than in 8 times in comparison to control, confirming the essential role of Cp in the formation of resistance phenomenon. Administration of cisplatin together with I led to effective inhibition of tumor in groups with T8 and T8*, indicating decreased resistance in the group T8*. Greater reduction of Cp levels was observed in the groups with T8* upon administration of the rhenium-platinum antitumor system, than in groups with T8, that underlines the importance of further investigations of the dirhenium(III) compounds in the resistance to cytostatics cancer models. Some mechanisms concerning the regulation of copper homeostasis and properties of nano-composites are discussed.
机译:当代对镀铂抗性机制的当代研究表明,铜代谢在癌症患者中的关键作用,并提出了通过调制铜传输机制来减弱阻力的可能方法。在该静脉中,刺激性(CP)水平的调查 - 血液中的主要铜蛋白,在细胞抑制剂给药时含有肿瘤的动物的实验中是局部的,非常重要。在常规(t8)的肿瘤大鼠血清中测量CP的浓度,并在施用顺铂和四点键合罗烯(III)化合物二氯替硝酸 - μ-异丁替替替辛基酮(T8 *)癌癌(Thlotin )(i)以不同的药物形式。结果表明,T8组肿瘤的发展导致CP浓度的3.7次和T8 *组 - 与控制相比超过8次,确认CP在形成抵抗现象中的基本作用。将顺铂与我一起施用,导致具有T8和T8 *的基团的肿瘤有效抑制,表明T8 *组中的抗性降低。在施用铼 - 铂抗肿瘤系统的基团中观察到在铼 - 铂抗肿瘤系统的基团中观察到CP水平的更大减少,而不是与T8的基团,这强调了进一步研究狄吩(III)化合物在对细胞抑制剂癌模型的抗性中的重要性的重要性。讨论了一些关于调节铜稳态和纳米复合材料性能的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号